Efficacy, tolerability, and bone density outcomes of elagolix with add-back therapy for endometriosis-associated pain: twelve months of an ongoing randomized phase 3 trial
American Journal of Obstetrics and Gynecology · 2024-12 · 231 (6) · 630.e1-630.e13
DOI: 10.1016/j.ajog.2024.06.040 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift American Journal of Obstetrics and Gynecology, 2024-12. Verfasst von Charles E Miller und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Advocate Lutheran General Hospital, the Advanced Gynecologic Surgery Institute, Park Ridge, IL. Electronic a…. Hauptthemen laut MEDLINE: Bone Density, Dysmenorrhea, Endometriosis, Hydrocarbons, Fluorinated. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AbbVie Inc.
Abstract (Originalsprache)
BACKGROUND: Elagolix, an approved oral treatment for endometriosis-associated pain, has been associated with hypoestrogenic effects when used as monotherapy. Hormonal add-back therapy has the potential to mitigate these effects. OBJECTIVE: To evaluate efficacy, tolerability, and bone density outcomes of elagolix 200 mg twice daily with 1 mg estradiol/0.5 mg norethindrone acetate (add-back) therapy once daily compared with placebo in premenopausal women with moderate-to-severe endometriosis-associated pain. STUDY DESIGN: This ongoing, 48-month, phase 3 study consists of a 12-month double-blind period, with randomization 4:1:2 to elagolix 200 mg twice daily with add-back therapy, elagolix 200 mg twice daily monotherapy for 6 months followed by elagolix with add-back therapy, or placebo. The coprimary endpoints were proportion of patients with clinical improvement (termed "responders") in dysmenorrhea and nonmenstrual pelvic pain at month 6. We report 12-month results on efficacy of elagolix with add-back therapy vs placebo in reducing dysmenorrhea, nonmenstrual pelvic pain, dyspareunia, and fatigue. Tolerability assessments include adverse events and change from baseline in bone mineral density. RESULTS: A total of 679 patients were randomized to elagolix with add-back therapy (n=389), elagolix monotherapy (n=97), or placebo (n=193). Compared with patients randomized to placebo, a significantly greater proportion of patients randomized to elagolix with add-back therapy responded with clinical improvement in dysmenorrhea (62.8% vs 23.7%; P≤.001) and nonmenstrual pelvic pain (51.3% vs 36.8%; P≤.001) at 6 months. Compared with placebo, elagolix with add-back therapy produced significantly greater improvement from baseline in 7 hierarchically ranked secondary endpoints including dysmenorrhea (months 12, 6, 3), nonmenstrual pelvic pain (months 12, 6, 3), and fatigue (months 6) (all P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Advocate Lutheran General Hospital, the Advanced Gynecologic Surgery Institute, Park Ridge, IL. Electronic address: chuckmillermd@gmail.com.
- Department of Obstetrics and Gynecology, Columbia University, New York, NY.
- Seattle Clinical Research Center, Seattle, Wa.
- Department of Obstetrics and Gynecology, George Washington University School of Medicine, Washington, DC.
- AbbVie Inc, North Chicago, IL.
Förderung
- AbbVie Inc
Zitieren
APA
Miller, C. E., Kim, J. H., Kroll, R., Simon, J. A., Soliman, A. M., Thomas, J. W., Xu, Y., Ng, J., & Snabes, M. C. (2024). Efficacy, tolerability, and bone density outcomes of elagolix with add-back therapy for endometriosis-associated pain: twelve months of an ongoing randomized phase 3 trial. American Journal of Obstetrics and Gynecology, 231(6), 630.e1-630.e13. https://doi.org/10.1016/j.ajog.2024.06.040
Vancouver
Miller CE, Kim JH, Kroll R, Simon JA, Soliman AM, Thomas JW, et al. Efficacy, tolerability, and bone density outcomes of elagolix with add-back therapy for endometriosis-associated pain: twelve months of an ongoing randomized phase 3 trial. American Journal of Obstetrics and Gynecology. 2024;231(6):630.e1-630.e13. doi:10.1016/j.ajog.2024.06.040
BibTeX
@article{Miller2024,
author = {Miller, Charles E and Kim, Jin Hee and Kroll, Robin and Simon, James A and Soliman, Ahmed M and Thomas, James W and Xu, Yanqing and Ng, Juki and Snabes, Michael C},
title = {Efficacy, tolerability, and bone density outcomes of elagolix with add-back therapy for endometriosis-associated pain: twelve months of an ongoing randomized phase 3 trial},
journal = {American Journal of Obstetrics and Gynecology},
year = {2024},
volume = {231},
number = {6},
pages = {630.e1--630.e13},
doi = {10.1016/j.ajog.2024.06.040}
}
EUVIMED